Baseline demographics, neurologic deficits, and hyperacute treatment status
| Fibrinolysis Group | FAST Group | P Value | |
|---|---|---|---|
| No. of patients | 25 | 32 | |
| Age (yr) (mean) | 66.6 ± 10.2 | 68.3 ± 10.7 | .549 |
| Male | 21 (84%) | 22 (69%) | .184 |
| Hypertension | 11 (44%) | 21 (66%) | .103 |
| Diabetes mellitus | 7 (28%) | 9 (28%) | .992 |
| Atrial fibrillation | 8 (32%) | 11 (34%) | .850 |
| NIHSS score on admission (mean) | 19.9 ± 8.1 | 19.8 ± 8.7 | .965 |
| TOAST classification | .737 | ||
| Atherosclerosis | 14 (56%) | 15 (47%) | |
| Cardioembolism | 7 (28%) | 12 (37%) | |
| Mixed or unknown | 4 (16%) | 5 (16%) | |
| Use of intravenous rtPA | 7 (28%) | 12 (36%) | .35 |
| Time from onset to puncture (min) (mean) | 297.0 ± 125.1 | 281.4 ± 138.3 | .662 |
| Primary endovascular treatment | |||
| Urokinase | 22 (88%) | – | |
| rtPA | 2 (8%) | ||
| Tirofiban | 1 (4%) | ||
| Penumbra | – | 32 (100%) | |
| Rescue treatment methods | |||
| Stenting | 7 (28%) | 6 (18.8%) | |
| Tirofiban | 2 (8%) | 2 (6.3%) | |
| Abciximab | 2 (8%) | – | |
| Penumbra | 2 (8%) | ||
| Solitaire | – | 3 (9.4%) |
Note:—TOAST indicates Trial of Org 10172 in Acute Stroke Treatment.34